During the Annual Meeting of the American Society of Clinical Oncology (ASCO), Novartis released thes new overall survival analyzes (SG) and quality of life (QoL) that evaluate your CDK4/6 inhibitor in combination with endocrine therapy for patients with hormone receptor-positive/human epidermal growth factor receptor-negative (HR+/HER2-) metastatic breast cancer.
“Our treatment has shown consistency in positive overall survival and quality of life outcomes for pre- and postmenopausal advanced breast cancer patients. Recently in May 2022, an update was presented at the ESMO BC congress on results corroborating an extension of 5.6 years in the life of postmenopausal patients with advanced breast cancer”, an unprecedented result and new hope for patients, commented Dr. Arturo Quintanilla, Medical Lead of solid tumors at Novartis Mexico.
In an exploratory new analysis of data from the phase III MONALEESA-2 study, Novartis’ CDK4/6 inhibitor in combination with an endocrine therapy maintained the overall survival benefit for postmenopausal patients with HR+/HER2 metastatic breast cancer– treated in the first line, including patients who required a dose modification.
The median overall survival (OS) observed in this analysis was 66 months in patients with at least one dose reduction of the CDK4/6 inhibitor from the initial dose, compared with 60.6 months in patients who did not have a dose reduction. In addition, an OS benefit was observed in all subgroups of patients treated with this inhibitor and endocrine therapy.
We recommend you read:
“Patients are looking to live longer and maintain as much quality of life as possible. For that reason, being able to provide them with up to 67.6 months of survival with a relative reduction in the risk of death of 33% represents a breakthrough for us. This confirms the longest median overall survival ever recorded in HR+/HER2- metastatic breast cancer,” concluded Dr. Arturo Quintanilla.
